Fortress Biotech:Cyprium将在NDA批准后保留对任何PRV的所有权,并将获得版税以及高达1.29亿美元的里程碑付款
Fortress Biotech:Cyprium将在NDA批准后保留对任何PRV的所有权,并将获得版税以及高达1.29亿美元的里程碑付款
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.